This review offers a comprehensive perspective on NY‐ESO‐1 as a promising target for cancer immunotherapy, emphasising its role as a highly immunogenic tumour antigen and its capacity to elicit immune responses across various malignancies. This evidence concerns the gene CTAG1B and neoplasm.